Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IPIG 2025 | The success of the 2nd IPIG conference: moving the field of PNH forward

In this video, Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, King’s College Hospital NHS Foundation Trust, London, UK, highlights the success of the 2nd IPIG conference, noting the significant growth of the event since its first iteration in 2023. The diverse program aimed to cover the nuances of managing paroxysmal nocturnal hemoglobinuria (PNH) and identify research gaps that should be addressed to drive progress in the field. Dr Kulasekararaj praises the meeting’s format, which encouraged discussions and fostered a productive and engaging atmosphere. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Yeah, I think it’s a fantastic meeting. It is a very small crowd of focused physicians, allied healthcare professionals, and sponsors as well. And again, we did the first meeting in Harrogate two years back, which was a great success, but this is definitely tripled from a numbers perspective as well. We got a large, large group of more than 300 registered participants with a fantastic program with a mix of young investigators, people who’ve been in the field for many, many years as well...

Yeah, I think it’s a fantastic meeting. It is a very small crowd of focused physicians, allied healthcare professionals, and sponsors as well. And again, we did the first meeting in Harrogate two years back, which was a great success, but this is definitely tripled from a numbers perspective as well. We got a large, large group of more than 300 registered participants with a fantastic program with a mix of young investigators, people who’ve been in the field for many, many years as well. And the topics covered are not the bog-standard conventional treatment but diving very much into the nuances of managing PNH but also taking a back step to make sure we start from the beginning so people who are entering into the field of PNH also had some knowledge about understanding the gaps where research should be done as well. So overall, I thought this was a great success and obviously was the deliberate ploy by the organizers to keep the talks to 50% of the allocated time and give 50% of the time for discussion, which is always fantastic and the endless discussions does make the session a great success and hopefully tomorrow we’ll have similar discussions and in the poster session as well and we’ll always make sure that people want to come back although it’s going to be in two years that this is going to be a great thing. And it’s also, as you know, this is a small community so it’s fantastic to network ideas from other colleagues as well have time to talk to other colleagues and other investigators so we have multiple ideas so that we can take the field forward.

 

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Disclosures

Research support (to institution): Celgene/BMS, Novartis; Consultant: Samsung, Novo Nordisk, Alexion/AstraZeneca, Arrowhead Pharmaceuticals, Silence Therapeutics, AdaRx, Ono Pharma; Speaker’s fees: Alexion/AstraZeneca, Amgen, Celgene/BMS, Pfizer, Novartis, 
Ra Pharmaceuticals/UCB, Roche, Sobi, Janssen; Scientific advisory board/data
monitoring committee: Alexion/Astra Zeneca, Apellis, Amgen, Agios, BioCryst, Celgene/BMS, Geron, Novartis, Pfizer, Regeneron, Roche, Sobi, Janssen, Samsung.